Monday, 23 May 2005

This presentation is part of: Bench Top to Pilot Plant Posters

A Novel IGF-IR signaling inhibitor: A Challenge to Process Chemists

Joel S. Slade, Joginder Bajwa, Prasad Kapa, Hui Liu, John Calienni, James Vivelo, David Parker, Guang-Pei Chen, and Edwin Villhauer. Novartis Pharmaceutical Corp., East Hanover, NJ

A new and efficient synthesis of an advanced intermediate in the preparation of a novel Insulin-like Growth Factor I Receptor (IGF-IR) signaling inhibitor is described. The new route eliminates the problematic steps found in the Discovery synthesis (length, high vacuum distillations, chromatography) and establishes the crucial 1,3-cis stereochemistry of the cyclobutane ring in the early steps. The synthesis involves 5 linear steps and provides the API starting material in an overall yield of 20% as opposed to the original approach which utilized 21 steps (including purifications) and provided the same compound in an overall yield of 8%. The challenges involved in the design and execution of this new strategy will be described.

Back to Bench Top to Pilot Plant Posters
Back to The 37th Middle Atlantic Regional Meeting (May 22-25, 2005)